WO2002018944A3 - Mittel zur diagnose von tumoren - Google Patents

Mittel zur diagnose von tumoren Download PDF

Info

Publication number
WO2002018944A3
WO2002018944A3 PCT/EP2001/010020 EP0110020W WO0218944A3 WO 2002018944 A3 WO2002018944 A3 WO 2002018944A3 EP 0110020 W EP0110020 W EP 0110020W WO 0218944 A3 WO0218944 A3 WO 0218944A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumours
diagnosing
diagnosing tumours
dcoh
interacts
Prior art date
Application number
PCT/EP2001/010020
Other languages
English (en)
French (fr)
Other versions
WO2002018944A2 (de
Inventor
Von Strandmann Elke Pogge
Original Assignee
Von Strandmann Elke Pogge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Von Strandmann Elke Pogge filed Critical Von Strandmann Elke Pogge
Priority to AU2001289854A priority Critical patent/AU2001289854A1/en
Priority to DE10193655T priority patent/DE10193655D2/de
Priority to US10/362,843 priority patent/US20040048317A1/en
Publication of WO2002018944A2 publication Critical patent/WO2002018944A2/de
Publication of WO2002018944A3 publication Critical patent/WO2002018944A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft ein Mittel zur Diagnose von Tumoren, insbesondere maligner Tumore des menschlichen und tierischen Körpers unter Verwendung mindestens einer mit DCoH interagierenden Substanz zur in vitro Diagnose.
PCT/EP2001/010020 2000-08-30 2001-08-30 Mittel zur diagnose von tumoren WO2002018944A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001289854A AU2001289854A1 (en) 2000-08-30 2001-08-30 Means for diagnosing tumours
DE10193655T DE10193655D2 (de) 2000-08-30 2001-08-30 Mittel zur Diagnose von Tumoren
US10/362,843 US20040048317A1 (en) 2000-08-30 2001-08-30 Means for diagnosing tumours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042827.4 2000-08-30
DE10042827A DE10042827A1 (de) 2000-08-30 2000-08-30 Mittel zur Diagnose von Tumoren

Publications (2)

Publication Number Publication Date
WO2002018944A2 WO2002018944A2 (de) 2002-03-07
WO2002018944A3 true WO2002018944A3 (de) 2003-03-20

Family

ID=7654456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010020 WO2002018944A2 (de) 2000-08-30 2001-08-30 Mittel zur diagnose von tumoren

Country Status (4)

Country Link
US (1) US20040048317A1 (de)
AU (1) AU2001289854A1 (de)
DE (2) DE10042827A1 (de)
WO (1) WO2002018944A2 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403712A (en) * 1991-12-17 1995-04-04 The Board Of Trustees Of The Leland Stanford Jr. University Transcription cofactor assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403712A (en) * 1991-12-17 1995-04-04 The Board Of Trustees Of The Leland Stanford Jr. University Transcription cofactor assay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ESKINAZI RALLY ET AL: "Overexpression of pterin-4a-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 in human colon cancer.", AMERICAN JOURNAL OF PATHOLOGY, vol. 155, no. 4, October 1999 (1999-10-01), pages 1105 - 1113, XP002202374, ISSN: 0002-9440 *
POGGE V STRANDMANN E ET AL: "ECTOPIC PIGMENTATION IN XENOPUS IN RESPONSE TO DCOH/PCD, THE COFACTOR OF HNF1 TRANSCRIPTION FACTOR/PTERIN-4 ALPHA-CARBINOLAMINE DEHYDRATASE", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 91, no. 1/2, 2000, pages 53 - 60, XP000946160, ISSN: 0925-4773 *
STRANDMANN POGGE VAN E ET AL: "DEVELOPMENTAL EXPRESSION OF THE MATERNAL PROTEIN XDCOH, THE DIMERIZATION COFACTOR OF THE HOMEOPROTEIN LFB1 (HNF1)", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 121, no. 4, 1995, pages 1217 - 1226, XP000946168, ISSN: 0950-1991 *
V STRANDMANN ELKE POGGE ET AL: "Dimerization co-factor of hepatocyte nuclear factor 1/pterin-4alpha-carbinolamine dehydratase is necessary for pigmentation in Xenopus and overexpressed in primary human melanoma lesions.", AMERICAN JOURNAL OF PATHOLOGY, vol. 158, no. 6, June 2001 (2001-06-01), pages 2021 - 2029, XP002202375, ISSN: 0002-9440 *

Also Published As

Publication number Publication date
AU2001289854A1 (en) 2002-03-13
US20040048317A1 (en) 2004-03-11
WO2002018944A2 (de) 2002-03-07
DE10042827A1 (de) 2002-03-14
DE10193655D2 (de) 2003-07-17

Similar Documents

Publication Publication Date Title
MXPA03000044A (es) Promocion de la salud de todo el cuerpo.
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
HK1030363A1 (en) Noninvasive vaccination through the skin
IT1316267B1 (it) Innesto doppio, in particolare per autoveicolo.
WO2001072822A3 (fr) Genes impliques dans les maladies inflammatoires de l"intestin et leur utilisation
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
IL143739A0 (en) Diagnostic assay
GB0016392D0 (en) Skin diagnostic aid
WO2002027315A3 (en) Compounds with a branched linker
MXPA03006629A (es) Composicion para el cuidado de la piel.
HRP20050142A2 (en) Steroid conjugates, preparation thereof and the use thereof
AU2001273999A1 (en) Fluorescein isothiocyanate (fitc) sinistrin, its production and use
WO2002066075A3 (en) Biotin-derivatives and their conjugates with chelating agents
WO2002018944A3 (de) Mittel zur diagnose von tumoren
WO2002024738A1 (en) β-CATENIN NUCLEAR LOCALIZED PROTEIN
AU2002210438A1 (en) Diagnosis of diseases which are associated with cd24
MXPA03007634A (es) Derivados de imidazolidina, su preparacion, su uso y preparaciones farmaceuticas que los contienen.
MXPA03006162A (es) Derivados de mikanolida, su preparacion y sus usos terapeuticos.
IL145279A0 (en) Antibodies against caspase-8, their preparation and use
ZA997637B (en) Substituted cycloheptenes, their preparation and use.
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REF Corresponds to

Ref document number: 10193655

Country of ref document: DE

Date of ref document: 20030717

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10193655

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 10362843

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP